Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

Published

Journal Article

Invasive fungal infection (IFI) is a serious threat after allogeneic hematopoietic cell transplant (HCT). This multicenter, randomized, double-blind trial compared fluconazole (N = 295) versus voriconazole (N = 305) for the prevention of IFI in the context of a structured fungal screening program. Patients undergoing myeloablative allogeneic HCT were randomized before HCT to receive study drugs for 100 days, or for 180 days in higher-risk patients. Serum galactomannan was assayed twice weekly for 60 days, then at least weekly until day 100. Positive galactomannan or suggestive signs triggered mandatory evaluation for IFI. The primary endpoint was freedom from IFI or death (fungal-free survival; FFS) at 180 days. Despite trends to fewer IFIs (7.3% vs 11.2%; P = .12), Aspergillus infections (9 vs 17; P = .09), and less frequent empiric antifungal therapy (24.1% vs 30.2%, P = .11) with voriconazole, FFS rates (75% vs 78%; P = .49) at 180 days were similar with fluconazole and voriconazole, respectively. Relapse-free and overall survival and the incidence of severe adverse events were also similar. This study demonstrates that in the context of intensive monitoring and structured empiric antifungal therapy, 6-month FFS and overall survival did not differ in allogeneic HCT recipients given prophylactic fluconazole or voriconazole. This trial was registered at www.clinicaltrials.gov as NCT00075803.

Full Text

Duke Authors

Cited Authors

  • Wingard, JR; Carter, SL; Walsh, TJ; Kurtzberg, J; Small, TN; Baden, LR; Gersten, ID; Mendizabal, AM; Leather, HL; Confer, DL; Maziarz, RT; Stadtmauer, EA; Bolaños-Meade, J; Brown, J; Dipersio, JF; Boeckh, M; Marr, KA; Blood and Marrow Transplant Clinical Trials Network,

Published Date

  • December 9, 2010

Published In

Volume / Issue

  • 116 / 24

Start / End Page

  • 5111 - 5118

PubMed ID

  • 20826719

Pubmed Central ID

  • 20826719

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2010-02-268151

Language

  • eng

Conference Location

  • United States